Product Name: CDC7 (373-379) pT376
Product Number: PE-04AJE99
| Size: | 200 µg | Price: | 42.00 | |
| 1 mg | $US | 84.00 | ||
| 5 mg | 185.00 |
Peptide Name: CDC7 (373-379) pT376
Product Use: Services as a blocking peptide for use with the CDC7-pT376 rabbit polyclonal antibody (Cat. No.: AB-PK558) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Originally suggested to be stimulatory based on loss of phosphotransferase activity with an alanine substitution. However, it is predicted to be inhibitory for phosphotransferase activity. This phosphosite is located in the kinase activation loop just before the catalytic subdomain VIII.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RAG-pT-PGF
Product Use: Services as a blocking peptide for use with the CDC7-pT376 rabbit polyclonal antibody (Cat. No.: AB-PK558) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Originally suggested to be stimulatory based on loss of phosphotransferase activity with an alanine substitution. However, it is predicted to be inhibitory for phosphotransferase activity. This phosphosite is located in the kinase activation loop just before the catalytic subdomain VIII.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: RAG-pT-PGF
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 957.99 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: CDC7 - pT376 phosphosite-specific antibody (Cat. No.: AB-PK558)
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 957.99 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: CDC7 - pT376 phosphosite-specific antibody (Cat. No.: AB-PK558)
Scientific Background: CDC7 is a protein-serine/threonine kinase that is important for the G1/S transition in the cell division cycle. The protein product may phosphorylate critical substrates in G1/S phase transition and DNA replication. CDC7 can also phosphorylate MCM2 and MCM3. It is activated by phosphorylation at T376 in the kinase activation loop by CDK1 and CDK2. It also requires binding to activator of S-phase kinase (ASK)/DBF4B to be fully stimulated. It may be an oncoprotein (OP) as over-expression of CDC7 may be associated with neoplastic tumour transformation. RNAi inhibition of CDC7 induces an abortive S phase and apoptotic cell death in p53-mutant ErbB2-overexpressing and triple-negative (ER-/PR-/ErbB2-) breast cancer cell lines, but not in untransformed breast epithelial cells. Consequently, CDC7 appears to represent a potent and highly specific anticancer target in ErbB2-overexpressing and triple-negative breast cancers. It is also a suitable target for treatment of other types of cancer, including pancreatic cancer.
© Kinexus Bioinformatics Corporation 2017